A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies

Bone Marrow Transplantation

Volumn 18, Issue 3, 1996, Pages 495-499

  Vey, N ^a   De Prijck, B ^a   Faucher, C ^a   Stoppa, A M ^a   Sainty, D ^a   Lafage, M ^a   Bouabdallah, R ^a   Chabannon, Ch ^a   Camerlo, J ^a   Gastaut, J A ^a   Maraninchi, D ^a   Blaise, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Acute leukemia; Allogeneic bone marrow transplantation; Busulfan; Chronic myelogenous leukemia; Melphalan

Indexed keywords

BILIRUBIN; BUSULFAN; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LIVER TOXICITY; LYMPHOMA; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME; VEIN OCCLUSION; VIRUS ENCEPHALITIS; VIRUS INFECTION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSION; MALE; MELPHALAN; MIDDLE AGED; PILOT PROJECTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 10144233451     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Appelbaum FR, Clift RA, Buckner CD et al. Allogeneic marrow transplantation for acute non-lymphoblastic leukemia after first relapse. Blood 1983; 61: 949-955.
2. Woods WG, Nesbit ME, Ramsay NKC et al. Intensive therapy followed by bone marrow transplantation on patients with acute lymphocytic leukemia in second or subsequent remission: determination of prognostic factors (a report from the University of Minnesota Bone Marrow Transplantation Team). Blood 1983; 61: 1182-1186.
3. Zander AR, Dicke KA, Keating M et al. Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy. Cancer 1985; 56: 1374-1379.
4. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986: 104: 155-163.
5. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
6. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2040.
7. Ringdén O, Ruutu T, Remberger M et al for the Nordic Bone Marrow Transplantation Group. A randomized trial comparing busulfan with total body irradiation as conditioning allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
8. Blaise D, Maraninchi D, Archimbaud E et al for the Groupe d'Etude de la Greffe de Moelle Osseuse. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578-2582.
9. Tutschka PJ, Santos GW. Bone marrow transplantation in the busulfan-treated rat III. Relationship between myelosuppression and immunosuppression for conditioning marrow recipients. Transplantation 1977; 24: 52-62.
10. Buckner CD, Dillingham LA, Giddens WE Jr, Thomas ED. Toxicologie and marrow transplantation studies of rhesus monkeys given dimethylmyleran. Exp Hematol 1975; 3: 275-288.
11. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
12. Maraninchi D, Pico JL, Hartmann O et al. High dose melphalan with or without bone marrow transplantation: a study of dose-effect in patients with refractory and/or relapsed acute leukemia. Cancer Treat Rep 1986; 70: 445-448.
13. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-835.
14. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
15. Bertheas MF, Maraninchi D, Lafage M et al. Partial chimerism after T-cell depleted allogeneic bone marrow transplantation in leukemic HLA-matched patients: a cytogenetic documentation. Blood 1988; 72: 89-93.
16. Gabert J, Thuret I, Lafage M et al. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation. Lancet 1989; 2: 1125-1128.
17. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-462.
18. Clift RA, Buckner CD, Thomas ED et al. Allogeneic marrow transplantation using fractionated total body irradiation in patients with acute lymphoblastic leukemia in relapse. Leukemia Res 1982; 6: 409-412.
19. Chao NJ, Forman SJ, Schmidt GM et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood 1991; 78: 1923-1927.
20. Chan JY, Bordigoni P, Souillet G et al. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of patients. Bone Marrow Transplant 1991; 7: 1-4.
21. Marit G, Boiron JM, David B et al. Cyclophosphasmide, melphalan and TBI as conditioning regimen prior to transplantation for high-risk patients. Bone Marrow Transplant 1988; 3: 315 (Abstr.).
22. Lynch MHE, Petersen FB, Appelbaum FR et al. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant 1995; 15: 59-64.
23. Weaver CH, Bensinger WI, Appelbaum FR et al. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-817.
24. Devergie A, Blaise D, Attal M et al. for the French Society of Bone Marrow Graft (SFGM). Allogeneic bone marrow transplantation for chronic myelogenous leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263-2268.
25. Matsuyama T, Kojima S, Kato K. Bone marrow transplantation following a regimen containing melphalan for acute myelogenous leukemia in childhood. Int Soc Paed Oncol XXVth Meeting, Paris, September 20-24, 1994 (Abstr.)
26. Reiffers J, Gaspard MH, Maraninchi D et al. Comparison of allogeneic and autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukemia in first remission: a prospective controlled trial. Br J Haematol 1989; 72: 57-63.
27. Martino R, Badell I, Sureda A et al. High-dose busulfan and melphalan before bone marrow transplantation for acute non-lymphoblastic leukemia. Bone Marrow Transplant 1995; 16: 209-210.
28. van Bisien K, Demuynck H, Lemaistre CF et al. High-dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant 1995; 15: 321-323.
29. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
30. Körbling M, Przepioka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
31. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
32. Uharek L, Gassmann W, Glass B, Steinmann J et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 1992; 79: 1612-1621.
33. Cony-Makhoul P, Marit G, Boiron JM et al. Busulfan and melphalan prior to autologous transplantation for myeloid malignancies. Bone Marrow Transplant 1995; 16: 69-70.
34. Srivastava A, Bradstock KF, Szer J et al. Busulfan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 1993; 12: 323-326.
35. Alegre A, Lamana M, Arranz M et al. Busulfan and melphalan as conditioning regimen for autologous blood stem cell transplantation in multiple myeloma. Br J Haematol 1995; 91: 380-386.
36. Clift RA, Buckner CD, Thomas ED et al. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243-258.
37. Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838-843.